ARCHIVES

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

ASC Survey Leads to Strategic Plan Development, Office In Washington

June 9, 1989

NCI To Voluntarily Spends $196 Million On Breast Cancer; Will Require Reallocation

November 13, 1992

Bypass Budget Omits Needless Words: Faster Progress to Cost $421 Million More

March 29, 1996

NCI Cooperative Group, Cancer Center Trials Listed

March 27, 2009

Cancer Letter Closes Out 1983, 10th Year

December 16, 1983

NCI Program: Hughes Institute Official To Head Cancer Biology

July 23, 1999